Hypertension and renal dysfunction in bone marrow transplant recipients

Area of Science:

• Nephrology
• Hematology
• Transplantation Medicine

Background:

• Bone marrow transplantation (BMT) is a critical treatment for various hematologic and oncologic conditions.
• Patients undergoing BMT are susceptible to significant complications, including renal and electrolyte disturbances.
• Understanding the incidence and contributing factors of these complications is vital for patient management.

Purpose of the Study:

• To investigate the incidence of acute renal failure, hypertension, and electrolyte disorders in BMT recipients.
• To compare the occurrence of these adverse events between patients receiving cyclosporine versus cyclophosphamide.
• To identify potential contributing factors to renal and electrolyte abnormalities post-BMT.

Main Methods:

• A randomized study involving 64 bone marrow transplant recipients.
• Patients were assigned to receive either cyclosporine or cyclophosphamide.
• Incidence of acute renal failure, hypertension, and hypomagnesemia was monitored and compared between groups.

Main Results:

• High incidence rates observed: 64% acute renal failure, 75% hypertension, 88% hypomagnesemia.
• Cyclosporine treatment was associated with a greater incidence of diastolic hypertension and hypomagnesemia.
• Hypomagnesemia resulted from renal magnesium wasting; proteinuria was nearly universal, with 21% exhibiting nephrotic-range proteinuria.

Conclusions:

• Hypertension, renal failure, and hypomagnesemia are common complications following bone marrow transplantation.
• While cyclosporine may exacerbate these issues, other factors like aminoglycoside antibiotics likely play a significant role.
• Renal function abnormalities were transient in observed patients, with recovery over one to three years.